Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $2,100 | $600 | $1,500 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2,846 | $766 | $442 | $1,188 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$575 | -$110 | -$4,646 | -$280 |
| Operating Expenses | $2,271 | $2,756 | -$2,562 | $2,408 |
| Operating Income | -$2,271 | -$2,756 | $2,562 | -$2,408 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $18 | $69 | -$487 | -$591 |
| Pre-Tax Income | -$2,253 | -$2,687 | $2,075 | -$1,795 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,253 | -$2,687 | $1,037 | -$897 |
| % Margin | – | – | – | – |
| EPS | -0.11 | -0.13 | 0.059 | -0.053 |
| % Growth | 15.4% | -318.9% | 211.9% | – |
| EPS Diluted | -0.11 | -0.13 | 0.059 | -0.053 |
| Weighted Avg Shares Out | 20,161 | 20,161 | 17,478 | 16,912 |
| Weighted Avg Shares Out Dil | 20,161 | 20,161 | 17,478 | 16,912 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19 | $148 | $36 | $6 |
| Interest Expense | $1 | $8 | $524 | $28 |
| Depreciation & Amortization | $0 | $3 | -$1,281 | $1,204 |
| EBITDA | -$2,252 | -$5,361 | $1,317 | -$563 |
| % Margin | – | – | – | – |